US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

26.03

-0.0400-0.15%

Post-market: 26.030.00000.00%19:59 EST

Volume:2.85M

Turnover:74.27M

Market Cap:1.40B

PE:-5.75

High:27.79

Open:26.19

Low:25.87

Close:26.07

52wk High:44.60

52wk Low:6.11

Shares:53.68M

Float Shares:21.07M

Volume Ratio:5.23

T/O Rate:13.52%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5278

EPS(LYR):-11.8940

ROE:-68.33%

ROA:-33.72%

PB:7.11

PE(LYR):-2.19

Loading ...

Overview Company News Filings

Zenas BioPharma Grants Inducement Stock Options and RSUs to New Hires

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma added to Best Ideas List at Wedbush

Why Zenas BioPharma (ZBIO) Is Up 17.4% After Positive Phase 2 Obexelimab MS Data And What's Next

Simply Wall St.

Director Patricia L. Allen Reports Acquisition of Zenas Biopharma Common Shares

Zenas Biopharma Launches Amended Short-Term Incentive Plan for Employees

Evercore ISI Reaffirms Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.

Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions

Zenas Biopharma Announces Late-Breaking Platform Presentation of Results From Phase 2 Moonstone Trial of Obexelimab in Relapsing Multiple Sclerosis at Actrims Forum 2026

THOMSON REUTERS

Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

A Big Boss Bet on Zenas BioPharma’s Future

Zenas Biopharma CEO Leon O. Moulder Jr. Reports Acquisition of Common Shares

Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan

Zenas Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Zenas Biopharma Unveils Pipeline Strategy Targeting Autoimmune and Multiple Sclerosis Markets

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet

Benzinga_recent_news

Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ZBIO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":26.03,"timestamp":1772053200000,"preClose":26.07,"halted":0,"volume":2847890,"hourTrading":{"tag":"盘后","latestPrice":26.03,"preClose":26.03,"latestTime":"19:59 EST","volume":4703,"amount":122400.14,"timestamp":1772067551432,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.001534330648254666,"floatShares":21071865,"shares":53679166,"eps":-4.527832,"marketStatus":"Closed","change":-0.04,"latestTime":"02-25 16:00:00 EST","open":26.19,"high":27.79,"low":25.87,"amount":74271288.09701,"amplitude":0.073648,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-4.527832,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772096400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":26.07,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":26.41,"preClose":26.07,"latestTime":"09:29 EST","volume":18,"amount":474.38000999999997,"timestamp":1772029799961,"change":0.34,"changeRate":0.013042,"amplitude":0.003836},"postHourTrading":{"tag":"盘后","latestPrice":26.03,"preClose":26.03,"latestTime":"19:59 EST","volume":4703,"amount":122400.14,"timestamp":1772067551432,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":5.232997,"impliedVol":0.9901,"impliedVolPercentile":0.54},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":21071865,"roa":"-33.72%","roe":"-68.33%","lyrEps":-11.893967,"volumeRatio":5.232997,"shares":53679166,"dividePrice":0,"high":27.79,"amplitude":0.073648,"preClose":26.07,"low":25.87,"week52Low":6.11,"pbRate":"7.11","psRate":"93.15","week52High":44.6,"institutionHeld":0,"latestPrice":26.03,"eps":-4.527832,"divideRate":0,"volume":2847890,"delay":0,"ttmEps":-4.527832,"open":26.19,"prevYearClose":36.31,"prevWeekClose":25.88,"prevMonthClose":18.37,"prevQuarterClose":36.31,"fiveDayClose":26.68,"twentyDayClose":20.07,"sixtyDayClose":40.53},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.87,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-1.22},{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25},{"market":"US","date":"2025-05-15","symbol":"ZBIO","fiscalQuarterEnding":"2025/03","expectedEps":-1.15,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747281600000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2024/09","expectedEps":13,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-5.02}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.25,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1768021200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2026-02-24","current":-5.971953,"percent":0.254848,"low":-19.592941,"twenty":-9.909357,"median":-4.030954,"eighty":-2.50709,"high":-1.802568,"avg":-5.78742,"sd":4.142268,"marketCap":1403173399},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-12","current":-4.798483,"twenty":-4.881439,"median":-2.99503,"eighty":-2.389351,"marketCap":849365013},{"date":"2025-09-19","current":-4.629572,"twenty":-4.881439,"median":-3.063777,"eighty":-2.399463,"marketCap":819466690},{"date":"2025-09-26","current":-4.429735,"twenty":-4.835595,"median":-3.074895,"eighty":-2.402603,"marketCap":784094028},{"date":"2025-10-03","current":-4.984046,"twenty":-4.911724,"median":-3.083269,"eighty":-2.409912,"marketCap":882211057},{"date":"2025-10-10","current":-6.604159,"twenty":-5.180553,"median":-3.135974,"eighty":-2.413574,"marketCap":1168982288},{"date":"2025-10-17","current":-5.759607,"twenty":-5.320916,"median":-3.162575,"eighty":-2.420654,"marketCap":1019490677},{"date":"2025-10-24","current":-5.949928,"twenty":-5.76722,"median":-3.174048,"eighty":-2.42495,"marketCap":1053178928},{"date":"2025-10-31","current":-9.035303,"twenty":-6.083769,"median":-3.188498,"eighty":-2.432369,"marketCap":1599311910},{"date":"2025-11-07","current":-9.81546,"twenty":-6.198298,"median":-3.245204,"eighty":-2.444339,"marketCap":1737405107},{"date":"2025-11-14","current":-10.08009,"twenty":-6.457611,"median":-3.282468,"eighty":-2.446909,"marketCap":1914199059},{"date":"2025-11-21","current":-9.848299,"twenty":-7.258864,"median":-3.371139,"eighty":-2.451734,"marketCap":1870182143},{"date":"2025-11-28","current":-10.976161,"twenty":-8.972029,"median":-3.394997,"eighty":-2.453948,"marketCap":2084362015},{"date":"2025-12-05","current":-10.772637,"twenty":-9.459248,"median":-3.515773,"eighty":-2.459247,"marketCap":2045713016},{"date":"2025-12-12","current":-11.366249,"twenty":-9.83041,"median":-3.643766,"eighty":-2.466418,"marketCap":2158439264},{"date":"2025-12-19","current":-9.913314,"twenty":-9.980024,"median":-3.678075,"eighty":-2.469682,"marketCap":1882528351},{"date":"2025-12-26","current":-12.202958,"twenty":-10.134363,"median":-3.729636,"eighty":-2.472265,"marketCap":2317329596},{"date":"2026-01-02","current":-10.263827,"twenty":-10.232168,"median":-3.760324,"eighty":-2.476253,"marketCap":1949090517},{"date":"2026-01-09","current":-4.638651,"twenty":-10.207521,"median":-3.79333,"eighty":-2.479511,"marketCap":880875114},{"date":"2026-01-16","current":-5.633657,"twenty":-10.159019,"median":-3.831007,"eighty":-2.483289,"marketCap":1069825778},{"date":"2026-01-23","current":-5.766513,"twenty":-10.142278,"median":-3.88256,"eighty":-2.488034,"marketCap":1095054986},{"date":"2026-01-30","current":-5.902195,"twenty":-10.122491,"median":-3.950232,"eighty":-2.490604,"marketCap":1120820986},{"date":"2026-02-06","current":-5.938943,"twenty":-10.119664,"median":-3.975342,"eighty":-2.498305,"marketCap":1127799277},{"date":"2026-02-13","current":-7.380571,"twenty":-10.08009,"median":-4.008147,"eighty":-2.503456,"marketCap":1401563024},{"date":"2026-02-20","current":-7.637803,"twenty":-9.946669,"median":-4.026371,"eighty":-2.50452,"marketCap":1450411065},{"date":"2026-02-24","current":-7.389051,"twenty":-9.909357,"median":-4.030954,"eighty":-2.50709,"marketCap":1403173399}],"updateTime":1772046727990},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613297658","title":"Zenas BioPharma Grants Inducement Stock Options and RSUs to New Hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297658","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297658?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:15","pubTimestamp":1771622108,"startTime":"0","endTime":"0","summary":"Zenas BioPharma granted inducement equity awards to newly hired employees, consisting of non-qualified stock options covering 35,700 shares and 53,625 restricted stock units. The options have a 10-year term, an exercise price of $26.77 per share, and vest over four years with 25% vesting after one year and the remainder in 36 monthly installments; the RSUs vest in four equal installments on Feb. 15 of 2027, 2028, 2029 and 2030, subject to continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on February 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDLb4kY2h:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2210150020.SGD","ZBIO","LU2095319765.USD","BK4139","SG9999014021.USD","IE00B64PRP62.GBP","NDAQ","LU2210149790.SGD","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2613297504","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613297504","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613297504?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:15","pubTimestamp":1771622100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nTUA6NDPWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2613290902","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613290902","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613290902?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:15","pubTimestamp":1771622100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb.  20, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/20/3242153/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2612448877","title":"Zenas BioPharma added to Best Ideas List at Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2612448877","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612448877?lang=en_us&edition=fundamental","pubTime":"2026-02-18 19:55","pubTimestamp":1771415742,"startTime":"0","endTime":"0","summary":"Wedbush analyst Martin Fan is adding Outperform-rated Zenas BioPharma (ZBIO) to the Wedbush Best Ideas List as the firm sees a buying opportunity f...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-added-to-best-ideas-list-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-added-to-best-ideas-list-at-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2611483606","title":"Why Zenas BioPharma (ZBIO) Is Up 17.4% After Positive Phase 2 Obexelimab MS Data And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2611483606","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611483606?lang=en_us&edition=fundamental","pubTime":"2026-02-16 20:20","pubTimestamp":1771244420,"startTime":"0","endTime":"0","summary":"In early February 2026, Zenas BioPharma reported Phase 2 MoonStone trial data showing obexelimab met its primary endpoint in Relapsing Multiple Sclerosis, with a highly statistically significant reduction in new gadolinium-enhancing T1 lesions and a safety profile consistent with prior studies.\nAn interesting aspect for investors is that obexelimab reduced markers of neuroaxonal injury and maintained stable disability scores through 24 weeks, hinting at potentially meaningful disease control...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/why-zenas-biopharma-zbio-is-up-174-after-positive-phase-2-ob","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/why-zenas-biopharma-zbio-is-up-174-after-positive-phase-2-ob","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0158827781.USD","LU2271345857.HKD","LU0225283273.USD","LU0795875086.SGD","LU1244550494.USD","LU1989772923.USD","BK4534","LU2111349929.HKD","LU0795875169.SGD","LU2089283258.USD","LU1074936037.SGD","LU1244550577.SGD","LU1668664300.SGD","LU1720051108.HKD","BK4516","LU1791710400.SGD","LU0314104364.USD","LU1720051017.SGD","LU0106261372.USD","BK4127","LU1363072403.SGD","LU0528227936.USD","LU0106831901.USD","BK4588","LU1732800096.USD","LU1244550221.USD","LU0557290698.USD","IE00BKVL7J92.USD","LU2028103732.USD","LU1791710582.SGD","IE00BZ1G4Q59.USD","BK4585","LU1548497426.USD","LU2089284900.SGD","LU2357305700.SGD","LU2347655156.SGD","LU0234570918.USD","LU0320765646.SGD","BK4504","LU0006306889.USD","LU0267386448.USD","LU0882574139.USD","LU2133065610.SGD","LU1162221912.USD","BK4581","LU0912757837.SGD","LU0158827948.USD","ZBIO","LU0098860793.USD"],"gpt_icon":0},{"id":"2611195714","title":"Director Patricia L. Allen Reports Acquisition of Zenas Biopharma Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2611195714","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611195714?lang=en_us&edition=fundamental","pubTime":"2026-02-14 06:07","pubTimestamp":1771020427,"startTime":"0","endTime":"0","summary":"Patricia L. Allen, a director of Zenas Biopharma Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 13, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL3yfW8j:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Patricia L. Allen Reports Acquisition of Zenas Biopharma Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2611619544","title":"Zenas Biopharma Launches Amended Short-Term Incentive Plan for Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2611619544","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611619544?lang=en_us&edition=fundamental","pubTime":"2026-02-14 05:59","pubTimestamp":1771019941,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. has announced the approval of its Amended and Restated Short-Term Incentive Plan, effective January 1, 2026. The plan provides regular full- and part-time employees with the opportunity to earn annual discretionary cash bonuses based on company performance and individual achievement of specified goals. The plan is administered by the Board of Directors for executives and by the CEO and executive leadership team for other employees. All payouts are subject to review and approval by the administrators, and payments will be made no later than March 15 following the end of each calendar year. Employees must be employed through the payment date to receive any award. The company retains the right to amend or discontinue the plan at any time.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nNDL6ntyDV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2611157124","title":"Evercore ISI Reaffirms Their Buy Rating on Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611157124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611157124?lang=en_us&edition=fundamental","pubTime":"2026-02-13 21:17","pubTimestamp":1770988635,"startTime":"0","endTime":"0","summary":"Evercore ISI analyst Cory Kasimov maintained a Buy rating on Zenas BioPharma, Inc. yesterday and set a price target of $55.00. Kasimov covers the H...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-zenas-biopharma-inc-zbio-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/evercore-isi-reaffirms-their-buy-rating-on-zenas-biopharma-inc-zbio-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2610364090","title":"Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2610364090","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610364090?lang=en_us&edition=fundamental","pubTime":"2026-02-10 20:52","pubTimestamp":1770727920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2026 07:52 ET (12:52 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"gpt_icon":0},{"id":"2610637914","title":"Zenas Biopharma Reports Phase 2 MoonStone Trial Shows Obexelimab Significantly Reduces MS Lesions","url":"https://stock-news.laohu8.com/highlight/detail?id=2610637914","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610637914?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:05","pubTimestamp":1770638712,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. announced results from the Phase 2 MoonStone trial of obexelimab in patients with Relapsing Multiple Sclerosis . The data were presented in a late-breaking oral session at the ACTRIMS Forum 2026. The study met its primary endpoint, demonstrating a 95% relative reduction in new gadolinium-enhancing T1 lesions compared to placebo over weeks 8 and 12. Obexelimab was reported to be well tolerated, with no new safety signals observed. Additional 24-week data indicated robust and durable activity of obexelimab. The company is also advancing orelabrutinib in global Phase 3 trials for Primary Progressive Multiple Sclerosis and plans to initiate a Phase 3 trial in non-active Secondary Progressive Multiple Sclerosis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nNDL4F36Nr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","SG9999014013.SGD","LU2095319765.USD","BK4585","BK4112","LU2210150020.SGD","BK4588","SG9999014005.SGD","SG9999014021.USD","BK4139","IE00BKPKM429.USD","LU2210149790.SGD","NDAQ","SG9999014039.USD","ZBIO"],"gpt_icon":0},{"id":"2610963763","title":"Zenas Biopharma Announces Late-Breaking Platform Presentation of Results From Phase 2 Moonstone Trial of Obexelimab in Relapsing Multiple Sclerosis at Actrims Forum 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2610963763","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610963763?lang=en_us&edition=fundamental","pubTime":"2026-02-09 20:05","pubTimestamp":1770638700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260209:nTUA6NWCT5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2608690213","title":"Zenas BioPharma to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2608690213","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608690213?lang=en_us&edition=fundamental","pubTime":"2026-02-04 20:05","pubTimestamp":1770206700,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Feb.  04, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/04/3231918/0/en/Zenas-BioPharma-to-Present-at-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","SMMF","BK4139","LABU","ZBIO","BK4211"],"gpt_icon":0},{"id":"2608385693","title":"A Big Boss Bet on Zenas BioPharma’s Future","url":"https://stock-news.laohu8.com/highlight/detail?id=2608385693","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608385693?lang=en_us&edition=fundamental","pubTime":"2026-02-04 10:01","pubTimestamp":1770170488,"startTime":"0","endTime":"0","summary":"New insider activity at Zenas BioPharma, Inc. ( ($ZBIO) ) has taken place on February 3, 2026. CEO Leon Moulder scooped up 57,000 shares of Zenas B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/a-big-boss-bet-on-zenas-biopharmas-future-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/a-big-boss-bet-on-zenas-biopharmas-future-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2608833103","title":"Zenas Biopharma CEO Leon O. Moulder Jr. Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2608833103","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608833103?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:31","pubTimestamp":1770154269,"startTime":"0","endTime":"0","summary":"Leon O. Moulder Jr., Chief Executive Officer and Director of Zenas Biopharma Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on February 03, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLDCGTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas Biopharma CEO Leon O. Moulder Jr. Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2604919949","title":"Zenas BioPharma Grants Stock Options to New Employee Under Inducement Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919949","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919949?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:15","pubTimestamp":1768598107,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. has granted a newly hired employee non-qualified stock options to purchase 100,000 shares of the company’s common stock at an exercise price of $19.93 per share, matching the closing price on January 15, 2026. The options have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary of the employee’s start date and the remainder vesting in 36 equal monthly installments, contingent on continued employment.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire  on January 16, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDL9BbqzD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","LU2095319765.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014021.USD","LU2210150020.SGD","SG9999014005.SGD","SG9999014013.SGD","NDAQ","IE00B64PRP62.GBP","BK4112","IE00BGHQF748.EUR","SG9999014039.USD","LU2210149790.SGD","LU0314104364.USD","ZBIO","BK4585"],"gpt_icon":0},{"id":"2604182919","title":"Zenas Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604182919","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604182919?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:15","pubTimestamp":1768598100,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nTUA8WWJBB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2604919470","title":"Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2604919470","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604919470?lang=en_us&edition=fundamental","pubTime":"2026-01-17 05:15","pubTimestamp":1768598100,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan.  16, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/16/3220558/0/en/Zenas-BioPharma-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"gpt_icon":0},{"id":"2602510429","title":"Zenas Biopharma Unveils Pipeline Strategy Targeting Autoimmune and Multiple Sclerosis Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2602510429","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602510429?lang=en_us&edition=fundamental","pubTime":"2026-01-12 21:13","pubTimestamp":1768223631,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. has released a corporate presentation outlining its progress and pipeline in the field of autoimmune diseases. The company highlighted plans for global marketing submissions for obexelimab in IgG4-related disease  and noted two late-stage franchise programs spanning four indications in immunology and inflammation (I&I). Additionally, two early-stage programs with best-in-class potential are in development, including an oral IL-17AA/AF inhibitor  and a brain-penetrant TYK2 inhibitor , both expected to enter Phase 1 trials. Zenas also reported achievement of primary and key secondary endpoints in the INDIGO Phase 3 IgG4-RD trial and shared data from the MoonStone Phase 2 relapsing multiple sclerosis trial. The company is positioning itself as a global, fully-integrated biopharmaceutical entity with commercial presence across multiple therapeutic areas, including rheumatology, multiple sclerosis, and dermatology. You can access the full presentation through the link b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260112:nNDL7c02lQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0},{"id":"2602580617","title":"Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet","url":"https://stock-news.laohu8.com/highlight/detail?id=2602580617","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602580617?lang=en_us&edition=fundamental","pubTime":"2026-01-10 22:01","pubTimestamp":1768053660,"startTime":"0","endTime":"0","summary":"The Benzinga Stock Whisper Index highlights five stocks seeing stronger than normal interest from readers and looks at the potential catalysts driving the attention.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/10/Stock-Whisper-Index.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/10/Stock-Whisper-Index.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/long-ideas/26/01/49829288/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-96","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/long-ideas/26/01/49829288/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet-96","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["LU0254981946.USD","BK4505","BK4535","BK4548","LU1868838027.USD","LU0048575426.USD","BK4532","BK4099","BK4581","BK4585","BK4139","LU0072463663.USD","LU0572108347.SGD","LU0823046494.USD","LU0265266980.USD","LU1861217088.USD","BK4531","LU0106259046.USD","LU0256859116.SGD","BK4509","MNTS","NIO.SI","LU2045819591.USD","BK4504","BK4574","GB00BDT5M118.USD","LU1861220207.SGD","LU0196696701.USD","BK4559","LU0456842615.SGD","LU0823046577.USD","LU1868837565.USD","BK4534","EVS.SI","LU0261950470.USD","NU","BK4555","LU0143863198.USD","BK4549","LU0320764599.SGD","LU1481012133.USD","LU0214875030.USD","LU2360107671.USD","LU0449509016.USD","LU0396314238.USD","BK4166","09866","LU0050427557.USD","BK4187","LU0531970944.HKD","BK4211","BK4551","BK4588","LU0531971322.HKD","LU0788109048.HKD","BK4526","LU0143863784.USD","LU0053687314.USD","IE00BGV7N243.SGD","LU0196696453.USD","LU0251143458.SGD","SOFI","ZBIO","NIO","LU0210535034.USD","LU0265267285.USD","BK4207","LU0086394185.USD","LU0708995583.HKD","LU2125910500.SGD","LU0052750758.USD","IE00B1B80R65.USD"],"gpt_icon":1},{"id":"2602304583","title":"Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2602304583","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602304583?lang=en_us&edition=fundamental","pubTime":"2026-01-10 10:43","pubTimestamp":1768013018,"startTime":"0","endTime":"0","summary":"Leon O. Moulder Jr., Chief Executive Officer of Zenas Biopharma Inc., reported the acquisition of common shares of Zenas Biopharma Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 09, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL79SP5f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas Biopharma CEO Leon O. Moulder Jr. Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":109,"code":"91000000","status":"200"}]}}